Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced a business ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work ...

Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...

Among the most famous demonstrations of genetic mutations driving infection outcome is severe combined immunodeficiency (SCID ...

A new clinical trial led by QIMR Berghofer, in collaboration with University of Sunshine Coast Clinical Trials Network has ...

More than seven million Americans have Alzheimer's disease, and two-thirds of them are women, according to the Alzheimer's Association. The O'Banion Lab at the Del Monte Institute for Neuroscience at ...

The interferon regulatory factor (IRF) family of transcription factors, pivotal for initiating antiviral type I interferon ...

A new clinical trial led by QIMR Berghofer, in collaboration with University of Sunshine Coast Clinical Trials Network has ...

Sobi to advance Gamifant in interferon-gamma-driven sepsis based on EMBRACE topline data: Stockholm Friday, January 9, 2026, 11:00 Hrs [IST] Sobi, a global biopharma company, anno ...

OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eligibility for a valuable ...